Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy in First-Line Treatment of Metastatic Melanoma in Slovenia
NCT07422779Recruiting
- Sponsor
- Institute of Oncology Ljubljana
- Start
- Mar 2022
- Primary completion
- Mar 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of pembrolizumab, nivolumab and ipilimumab in melanoma (2 arms), sponsored by Institute of Oncology Ljubljana. Primary endpoint: Objective Response Rate at 28 weeks. Started Mar 2022; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07422779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07422779.